Insight Molecular Diagnostics Inc. — Director's Dealing 2022

Aug 17, 2022

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Oncocyte Corp (OCX)
CIK: 0001642380
Period of Report: 2022-08-15

Reporting Person: Gutfreund John Peter (Director)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2022-08-15	Common Stock, no par value	A	10000	—	Acquired	10000	Direct
2022-08-15	Common Stock, no par value	P	25000	$0.93	Acquired	25000	Indirect

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2022-08-15	Option to Purchase Common Stock	$0.97	A	45000	Acquired	2032-08-15	Common Stock (45000)	Direct

Footnotes

F1: The Restricted Stock Units shall vest one year from the date of grant, subject to the Reporting Person's continued service as a director of the Issuer from the date of grant until the vesting date or, if earlier, until the next annual meeting of shareholders.

F2: The price of $0.93 per share represents a weighted average of prices ranging from $0.91 to $0.97 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F3: These securities are held by the minor children of the Reporting Person, and the Reporting Person has voting and dispositive control over such securities.

F4: Options shall vest one year from the date of grant, subject to the Reporting Person's continued service as a director of the Issuer from the date of grant until the vesting date or, if earlier, until the next annual meeting of shareholders.